Pancreatic neuroendocrine tumors: does chemotherapy work?

Area of Science:

• Oncology
• Gastroenterology
• Medical Oncology

Background:

• Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms with variable prognosis.
• Current treatments for advanced, unresectable pNETs include somatostatin analogs, everolimus, and sunitinib.
• Existing systemic therapies have limitations in response rates and toxicity, necessitating novel treatment strategies.

Framework:

• This review focuses on three abstracts presented at the 2014 ASCO Gastrointestinal Cancers Symposium.
• The abstracts evaluate the efficacy and safety of combination capecitabine and temozolomide therapy.
• The study population comprises patients with advanced, unresectable pancreatic neuroendocrine tumors.

Implementation:

• Combination capecitabine and temozolomide was administered to patients with advanced pNET.
• Outcomes such as response rates, progression-free survival, and toxicity were assessed.
• Data from the three abstracts were summarized to provide a comprehensive overview.

Implications:

• The combination of capecitabine and temozolomide demonstrates potential as a treatment option for advanced pNET.
• This regimen may represent a valuable addition to the treatment algorithm for metastatic pNET.
• Further investigation into this combination therapy is warranted to optimize its role in clinical practice.